Clinical Trial Update: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of nivolumab and relatlimab in metastatic melanoma patients who have not received prior immunotherapy has completed. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: John Kirkwood | Conditions: Melanoma | Phase 2 | Status: COMPLETED